Impact of quadrivalent influenza vaccine on public health and ă influenza-related costs in Australia
Identifieur interne : 000062 ( France/Analysis ); précédent : 000061; suivant : 000063Impact of quadrivalent influenza vaccine on public health and ă influenza-related costs in Australia
Auteurs : Aurelien Jamotte ; Chui Fung Chong ; Andrew Manton ; Berengere Macabeo ; Mondher Toumi [France]Source :
- BMC Public Health [ 1471-2458 ] ; 2016-07.
English descriptors
- mix :
Abstract
Background: Annual trivalent influenza vaccines (TIV) containing three ă influenza strains (A/H1N1, A/H3N2, and one B) have been recommended for ă the prevention of influenza. However, worldwide co-circulation of two ă distinct B lineages (Victoria and Yamagata) and difficulties in ă predicting which lineage will predominate each season have led to the ă development of quadrivalent influenza vaccines (QIV), which include both ă B lineages. Our analysis evaluates the public health benefit and ă associated influenza-related costs avoided which would have been ă obtained by using QIV rather than TIV in Australia over the period ă 2002-2012. ă Methods: A static model stratified by age group was used, focusing on ă people at increased risk of influenza as defined by the Australian ă vaccination recommendations. B-lineage cross-protection was accounted ă for. We calculated the potential impact of QIV compared with TIV over ă the seasons 2002-2012 (2009 pandemic year excluded) using Australian ă data on influenza circulation, vaccine coverage, hospitalisation and ă mortality rates as well as unit costs, and international data on vaccine ă effectiveness, influenza attack rate, GP consultation rate and working ă days lost. Third-party payer and societal influenza-related costs were ă estimated in 2014 Australian dollars. Sensitivity analyses were ă conducted. ă Results: Using QIV instead of TIV over the period 2002-2012 would have ă prevented an estimated 68,271 additional influenza cases, 47,537 GP ă consultations, 3,522 hospitalisations and 683 deaths in the population ă at risk of influenza. These results translate into influenza-related ă societal costs avoided of \46.5 million. The estimated impact of QIV ă was higher for young children and the elderly. The overall impact of QIV ă depended mainly on vaccine effectiveness and the influenza attack rate ă attributable to the mismatched B lineage. ă Conclusion: The broader protection offered by QIV would have reduced the ă number of influenza infections and its related complications, leading to ă substantial influenza-related costs avoided.
Url:
DOI: 10.1186/s12889-016-3297-1
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Hal, to step Corpus: 000149
- to stream Hal, to step Curation: 000149
- to stream Hal, to step Checkpoint: 000086
- to stream Main, to step Merge: 000378
- to stream Main, to step Curation: 000378
- to stream Main, to step Exploration: 000378
- to stream France, to step Extraction: 000062
Links to Exploration step
Hal:hal-01482357Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of quadrivalent influenza vaccine on public health and ă influenza-related costs in Australia</title><author><name sortKey="Jamotte, Aurelien" sort="Jamotte, Aurelien" uniqKey="Jamotte A" first="Aurelien" last="Jamotte">Aurelien Jamotte</name></author><author><name sortKey="Chong, Chui Fung" sort="Chong, Chui Fung" uniqKey="Chong C" first="Chui Fung" last="Chong">Chui Fung Chong</name></author><author><name sortKey="Manton, Andrew" sort="Manton, Andrew" uniqKey="Manton A" first="Andrew" last="Manton">Andrew Manton</name></author><author><name sortKey="Macabeo, Berengere" sort="Macabeo, Berengere" uniqKey="Macabeo B" first="Berengere" last="Macabeo">Berengere Macabeo</name></author><author><name sortKey="Toumi, Mondher" sort="Toumi, Mondher" uniqKey="Toumi M" first="Mondher" last="Toumi">Mondher Toumi</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221683" status="INCOMING"> <orgName>Pharmaco-Epidémiologie</orgName> <desc> <address> <addrLine>146 rue Léo-Saignat - 33076 Bordeaux Cedex</addrLine> <country key="FR"></country> </address> </desc> <listRelation> <relation active="#struct-91134" type="direct"></relation> <relation name="CICP 0005" active="#struct-303623" type="direct"></relation> </listRelation> <tutelles><tutelle active="#struct-91134" type="direct"><org type="institution" xml:id="struct-91134" status="OLD"> <orgName>Université Bordeaux Segalen - Bordeaux 2</orgName> <desc> <address> <addrLine>146 rue Léo Saignat - 33076 Bordeaux cedex</addrLine> <country key="FR"></country> </address> <ref type="url">http://www.univ-bordeauxsegalen.fr/</ref> </desc> </org></tutelle><tutelle name="CICP 0005" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno> <orgName>Institut National de la Santé et de la Recherche Médicale</orgName> <orgName type="acronym">INSERM</orgName> <desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine> <country key="FR"></country> </address> <ref type="url">http://www.inserm.fr</ref> </desc> </org></tutelle></tutelles></hal:affiliation><country>France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:hal-01482357</idno><idno type="halId">hal-01482357</idno><idno type="halUri">https://hal.archives-ouvertes.fr/hal-01482357</idno><idno type="url">https://hal.archives-ouvertes.fr/hal-01482357</idno><idno type="doi">10.1186/s12889-016-3297-1</idno><date when="2016-07">2016-07</date><idno type="wicri:Area/Hal/Corpus">000149</idno><idno type="wicri:Area/Hal/Curation">000149</idno><idno type="wicri:Area/Hal/Checkpoint">000086</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000086</idno><idno type="wicri:doubleKey">1471-2458:2016:Jamotte A:impact:of:quadrivalent</idno><idno type="wicri:Area/Main/Merge">000378</idno><idno type="wicri:Area/Main/Curation">000378</idno><idno type="wicri:Area/Main/Exploration">000378</idno><idno type="wicri:Area/France/Extraction">000062</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of quadrivalent influenza vaccine on public health and ă influenza-related costs in Australia</title><author><name sortKey="Jamotte, Aurelien" sort="Jamotte, Aurelien" uniqKey="Jamotte A" first="Aurelien" last="Jamotte">Aurelien Jamotte</name></author><author><name sortKey="Chong, Chui Fung" sort="Chong, Chui Fung" uniqKey="Chong C" first="Chui Fung" last="Chong">Chui Fung Chong</name></author><author><name sortKey="Manton, Andrew" sort="Manton, Andrew" uniqKey="Manton A" first="Andrew" last="Manton">Andrew Manton</name></author><author><name sortKey="Macabeo, Berengere" sort="Macabeo, Berengere" uniqKey="Macabeo B" first="Berengere" last="Macabeo">Berengere Macabeo</name></author><author><name sortKey="Toumi, Mondher" sort="Toumi, Mondher" uniqKey="Toumi M" first="Mondher" last="Toumi">Mondher Toumi</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221683" status="INCOMING"> <orgName>Pharmaco-Epidémiologie</orgName> <desc> <address> <addrLine>146 rue Léo-Saignat - 33076 Bordeaux Cedex</addrLine> <country key="FR"></country> </address> </desc> <listRelation> <relation active="#struct-91134" type="direct"></relation> <relation name="CICP 0005" active="#struct-303623" type="direct"></relation> </listRelation> <tutelles><tutelle active="#struct-91134" type="direct"><org type="institution" xml:id="struct-91134" status="OLD"> <orgName>Université Bordeaux Segalen - Bordeaux 2</orgName> <desc> <address> <addrLine>146 rue Léo Saignat - 33076 Bordeaux cedex</addrLine> <country key="FR"></country> </address> <ref type="url">http://www.univ-bordeauxsegalen.fr/</ref> </desc> </org></tutelle><tutelle name="CICP 0005" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno> <orgName>Institut National de la Santé et de la Recherche Médicale</orgName> <orgName type="acronym">INSERM</orgName> <desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine> <country key="FR"></country> </address> <ref type="url">http://www.inserm.fr</ref> </desc> </org></tutelle></tutelles></hal:affiliation><country>France</country></affiliation></author></analytic><idno type="DOI">10.1186/s12889-016-3297-1</idno><series><title level="j">BMC Public Health</title><idno type="ISSN">1471-2458</idno><imprint><date type="datePub">2016-07</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="mix" xml:lang="en"><term>quality</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"> <p>Background: Annual trivalent influenza vaccines (TIV) containing three ă influenza strains (A/H1N1, A/H3N2, and one B) have been recommended for ă the prevention of influenza. However, worldwide co-circulation of two ă distinct B lineages (Victoria and Yamagata) and difficulties in ă predicting which lineage will predominate each season have led to the ă development of quadrivalent influenza vaccines (QIV), which include both ă B lineages. Our analysis evaluates the public health benefit and ă associated influenza-related costs avoided which would have been ă obtained by using QIV rather than TIV in Australia over the period ă 2002-2012. ă Methods: A static model stratified by age group was used, focusing on ă people at increased risk of influenza as defined by the Australian ă vaccination recommendations. B-lineage cross-protection was accounted ă for. We calculated the potential impact of QIV compared with TIV over ă the seasons 2002-2012 (2009 pandemic year excluded) using Australian ă data on influenza circulation, vaccine coverage, hospitalisation and ă mortality rates as well as unit costs, and international data on vaccine ă effectiveness, influenza attack rate, GP consultation rate and working ă days lost. Third-party payer and societal influenza-related costs were ă estimated in 2014 Australian dollars. Sensitivity analyses were ă conducted. ă Results: Using QIV instead of TIV over the period 2002-2012 would have ă prevented an estimated 68,271 additional influenza cases, 47,537 GP ă consultations, 3,522 hospitalisations and 683 deaths in the population ă at risk of influenza. These results translate into influenza-related ă societal costs avoided of \46.5 million. The estimated impact of QIV ă was higher for young children and the elderly. The overall impact of QIV ă depended mainly on vaccine effectiveness and the influenza attack rate ă attributable to the mismatched B lineage. ă Conclusion: The broader protection offered by QIV would have reduced the ă number of influenza infections and its related complications, leading to ă substantial influenza-related costs avoided.</p> </div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Chong, Chui Fung" sort="Chong, Chui Fung" uniqKey="Chong C" first="Chui Fung" last="Chong">Chui Fung Chong</name><name sortKey="Jamotte, Aurelien" sort="Jamotte, Aurelien" uniqKey="Jamotte A" first="Aurelien" last="Jamotte">Aurelien Jamotte</name><name sortKey="Macabeo, Berengere" sort="Macabeo, Berengere" uniqKey="Macabeo B" first="Berengere" last="Macabeo">Berengere Macabeo</name><name sortKey="Manton, Andrew" sort="Manton, Andrew" uniqKey="Manton A" first="Andrew" last="Manton">Andrew Manton</name></noCountry><country name="France"><noRegion><name sortKey="Toumi, Mondher" sort="Toumi, Mondher" uniqKey="Toumi M" first="Mondher" last="Toumi">Mondher Toumi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000062 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000062 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= France
|étape= Analysis
|type= RBID
|clé= Hal:hal-01482357
|texte= Impact of quadrivalent influenza vaccine on public health and ă influenza-related costs in Australia
}}
| This area was generated with Dilib version V0.6.33. |  |